Co-Diagnostics, Inc. Announces Q3 2020 Earnings Release Date and Earnings Webcast
Co-Diagnostics, Inc. (Nasdaq: CODX) announced it will release its third quarter 2020 earnings on November 16, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics, Inc. (Nasdaq: CODX) announced it will release its third quarter 2020 earnings on November 16, 2020, after market close. An earnings call will be hosted at 4:30 PM EDT, featuring prepared remarks from CEO Dwight Egan and a Q&A session for analysts. The call will be recorded and later accessible on the company's website. Co-Diagnostics focuses on developing innovative molecular diagnostics technology and utilizes its proprietary methods to create tests for various industries, including infectious diseases.
Positive
- Scheduled earnings call on November 16, 2020, indicating transparency
- Opportunity for analysts to engage during the Q&A session
Negative
- None.
Details
News Market Reaction – CODX
The recorded move for CODX in the trading session of this news was +2.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its third quarter 2020 earnings on November 16, 2020 after the close of trading on that day, and will hold an earnings call at 4:30 pm EDT. The call is expected to consist of prepared remarks by Company CEO Dwight Egan.
Analysts providing coverage for Co-Diagnostics will also be invited participate in a question and answer session. All other participants can register for access to the webcast here.
The call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company's products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company's balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-q3-2020-earnings-release-date-and-earnings-webcast-301169371.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.